StocksMedium•13 November 2026•
1 min read
Fortress Biotech Revenue Grows 8% in Q3 Driven by Emrosi Sales
Key Facts
1Fortress Biotech's total revenue increased 8% to $19 million in the third quarter.
2Emrosi net sales reached $9 million on 40,000 total prescriptions.
Fortress Biotech's total revenue increased 8% to $19 million in the third quarter of 2026. The Motley Fool reported that Emrosi net sales reached $9 million, supported by 40,000 total prescriptions during the period.
FBIO closed at $1.99 on November 12, 2026, with the stock reaching a day high of $2.07 and a low of $1.92. These financial results indicate steady growth in key product sales for the biotechnology firm.